| Overview |
| bsm-52042M |
| CRISPR-Cas9 (1E8) Monoclonal Antibody |
| WB |
| Human, Others |
| Specifications |
| Unconjugated |
| Mouse |
| Recombinant fragment corresponding to Streptococcus pyogenes CRISPR-Cas9 (100-200aa) |
| Monoclonal |
| 100000000 |
| IgM |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 901176 |
| Q99ZW2 |
| CRISPR; Cas9; CRISPR-associated endonuclease Cas9/Csn1; SpyCas9; SpCas9; csn1 |
| CRISPR (clustered regularly interspaced short palindromic repeat) is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA) (Probable). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and this protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed by 3'-5' exonucleolytically. DNA-binding requires protein and both RNA species. Cas9 probably recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus nonself. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz